- Home
- HSHP vs ATAI Comparison
HSHP vs ATAI Comparison
Compare HSHP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- ATAI
- Stock Information
- Founded
- HSHP 2021
- ATAI 2018
- Country
- HSHP Bermuda
- ATAI Germany
- Employees
- HSHP N/A
- ATAI N/A
- Industry
- HSHP
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- ATAI Health Care
- Exchange
- HSHP Nasdaq
- ATAI Nasdaq
- Market Cap
- HSHP 248.0M
- ATAI 282.6M
- IPO Year
- HSHP 2023
- ATAI 2021
- Fundamental
- Price
- HSHP $4.59
- ATAI $1.47
- Analyst Decision
- HSHP
- ATAI Strong Buy
- Analyst Count
- HSHP 0
- ATAI 3
- Target Price
- HSHP N/A
- ATAI $10.50
- AVG Volume (30 Days)
- HSHP 223.2K
- ATAI 1.8M
- Earning Date
- HSHP 05-20-2025
- ATAI 05-14-2025
- Dividend Yield
- HSHP 10.15%
- ATAI N/A
- EPS Growth
- HSHP 1123.58
- ATAI N/A
- EPS
- HSHP 0.48
- ATAI N/A
- Revenue
- HSHP $123,580,000.00
- ATAI $308,000.00
- Revenue This Year
- HSHP $11.04
- ATAI $65.58
- Revenue Next Year
- HSHP $26.01
- ATAI N/A
- P/E Ratio
- HSHP $10.12
- ATAI N/A
- Revenue Growth
- HSHP 236.40
- ATAI N/A
- 52 Week Low
- HSHP $4.29
- ATAI $1.03
- 52 Week High
- HSHP $9.76
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- HSHP 37.02
- ATAI 52.47
- Support Level
- HSHP $4.48
- ATAI $1.15
- Resistance Level
- HSHP $4.84
- ATAI $1.44
- Average True Range (ATR)
- HSHP 0.25
- ATAI 0.13
- MACD
- HSHP -0.07
- ATAI 0.03
- Stochastic Oscillator
- HSHP 20.83
- ATAI 88.89
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.